Overview

Lucentis to Treat Pigment Epithelial Detachment

Status:
Completed

Trial end date:
2011-12-01

Target enrollment:

Participant gender:

Summary

Patients with Pigment Epithelial Detachments secondary to Age-Related Macular Degeneration (AMD) will receive intravitreal Lucentis monthly for 6 months in the hope of improving visual acuity from a baseline evaluation.

Phase:

Phase 2

Details

Lead Sponsor:

Lawson Health Research Institute

Collaborator:

Novartis Pharmaceuticals

Treatments:

Ranibizumab